Replicating and non-replicating viral vectors for vaccine development
about
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesProtective immunity and safety of a genetically modified influenza virus vaccineSang Froid in a time of trouble: is a vaccine against HIV possible?Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vectorPre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininEstimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine.Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Vaccine design for CD8 T lymphocyte responsesNovel viral vectored vaccines for the prevention of influenza.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesDNAVaxDB: the first web-based DNA vaccine database and its data analysis.Development of a Streptococcus gordonii vaccine strain expressing Schistosoma japonicum Sj-F1 and evaluation of using this strain for intranasal immunization in mice.Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.Development of replication-competent viral vectors for HIV vaccine delivery.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction.Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigsInduction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in SituReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerInduction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinantsHigh-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Nonviral delivery of self-amplifying RNA vaccines.HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 studyA Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.Recombinant adenovirus containing hyper-interleukin-6 and hepatocyte growth factor ameliorates acute-on-chronic liver failure in ratsUncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability.The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaquesMacaca mulatta, fascicularis and nemestrina in AIDS vaccine development.HIV/AIDS vaccines: a need for new concepts?Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.
P2860
Q24652185-5EB420AB-C7A9-4EF6-92E9-AF617CD2FD83Q26783897-2F195085-7FFC-4E4B-8446-1FA4498E3E0DQ27319783-2DFA7906-E3D6-4F9C-A7B4-8755574317AEQ27324763-FC61A760-7076-427B-BE40-DFEC1EBCF5F4Q27487961-87F763C7-3B81-4CAE-B244-885909066461Q28533970-BE0D02A7-C6F5-425E-AA9B-6F0057065EB3Q28731982-9C7AB70E-35B2-4E14-B327-9D4B86AD5490Q30151714-F0917FD2-976D-4120-94AD-7D9C45DDEDE8Q30375160-03CE3299-9F86-497F-B7FF-0329898480ABQ30411492-C973755B-3FC9-41CE-A715-19114388D36DQ30418570-FD8C432A-8F4B-458C-9FEB-3BA3BA127643Q30427591-ACF29616-8FED-484D-B7EE-E81D9B2F268CQ30841376-9DB56092-CA47-4E79-9A31-CB6D0E18017DQ31110824-B37671D5-74BD-486D-B47C-ECAE77CD310EQ33686890-BA42C872-23F0-4C8F-92E3-BBDA415BC044Q33694226-26A54337-11E6-49AB-9C0D-F768C74C1689Q33759392-21273D4C-D8F0-49BF-83F4-3175A3E5DD89Q33786140-305D3B18-4DB8-4548-BD55-252469C2A8A8Q34296144-2FF879E3-D4F3-4A4D-99EF-5DEE7C7E8986Q34741882-201403CF-BF2C-407F-96DB-B9095B976FBEQ35160124-523B7F97-65A4-494F-80BC-88F7DD834BA0Q35204547-D1822348-7FCB-4352-A195-2DA6337B9A1CQ35275117-48AE836B-15E5-465D-84CD-78DCA134CCB6Q35317858-7DA19C6B-4F4F-489A-BF24-D3F43858F707Q35600305-13B9C66B-D91C-4AB3-8886-6FAB571F1D74Q35826688-91BA2495-FED0-4863-A302-A6437EC0E291Q35949356-7FA75648-2D69-4EF2-B835-73722DB49F7FQ35973518-935109D3-B76D-4F66-8D88-065964985554Q35973549-11643370-0540-4DF0-B607-DD700AF09B55Q36009232-86ABE13C-1E0C-4DCA-983D-8E403310A6FCQ36221799-FC8E7530-D04A-4BCD-B617-F81EACB3DD31Q36249933-157EE780-9873-4C07-89E7-3537488FF8F7Q36621905-4E0EC682-3380-44E0-A632-46DE23B3BFC5Q36736786-A9C4D695-A0B5-4A19-8F70-14B592BF43B8Q36815008-6694EA1C-9FD6-4034-A559-4F53AE0DED6CQ37060986-B7A4F4B9-9025-47B3-AA5E-A262E5134550Q37181386-96F061BC-4373-4BA1-9E40-7517CBAD8E47Q37316026-86C83989-5685-4BBC-909F-6E30613FF822Q37344236-900BC2DA-5C40-4F41-97C5-154E4CE54B07Q37361294-9637AF05-79F8-4E8F-8BF1-F34B79E4806B
P2860
Replicating and non-replicating viral vectors for vaccine development
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Replicating and non-replicating viral vectors for vaccine development
@ast
Replicating and non-replicating viral vectors for vaccine development
@en
type
label
Replicating and non-replicating viral vectors for vaccine development
@ast
Replicating and non-replicating viral vectors for vaccine development
@en
prefLabel
Replicating and non-replicating viral vectors for vaccine development
@ast
Replicating and non-replicating viral vectors for vaccine development
@en
P2860
P1476
Replicating and non-replicating viral vectors for vaccine development
@en
P2093
Marjorie Robert-Guroff
P2860
P304
P356
10.1016/J.COPBIO.2007.10.010
P577
2007-12-11T00:00:00Z